Format

Send to

Choose Destination
J Psychopharmacol. 2005 Sep;19(5):483-7.

Mirtazapine treatment of generalized anxiety disorder: a fixed dose, open label study.

Author information

1
Department of Oncology and Neurosciences, Institute of Psychiatry, University 'G. D'Annunzio' of Chieti, Chieti, Italy. fgambi@unich.it.

Abstract

We investigated the efficacy of mirtazapine in the treatment of generalized anxiety disorder (GAD). Forty-four adult outpatients with GAD were treated openly with a fixed dose of mirtazapine (30 mg) for 12 weeks. The primary outcome measure was the change from baseline in total score on the Hamilton Rating Scale for Anxiety (HAM-A). The Clinical Global Impression of Improvement (CGI-I) was rated at the endpoint. Patients with a reduction of 50% or more on the HAM-A total score and a CGI-I score of 1 or 2 at endpoint were considered responders to treatment; remission was defined as a HAM-A score <or=7. At 12 weeks, response was achieved by 79.5% of the patients (n=35) and remission by 36.4% of patients (n=16). This study supports the notion that mirtazapine is an efficacious and well tolerated treatment for GAD. Limitations of the present study must be considered and further placebo-controlled trials are needed.

PMID:
16166185
DOI:
10.1177/0269881105056527
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center